Trials / Active Not Recruiting
Active Not RecruitingNCT05246514
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients With HER2-mutant Metastatic NSCLC Who Have Disease Progression on or After at Least One-line of Treatment (DESTINY-Lung05)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab deruxtecan | administered as an IV infusion |
Timeline
- Start date
- 2022-07-13
- Primary completion
- 2023-09-23
- Completion
- 2026-03-16
- First posted
- 2022-02-18
- Last updated
- 2025-08-28
- Results posted
- 2024-12-04
Locations
28 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05246514. Inclusion in this directory is not an endorsement.